The identification of this network was notable in light of two other observations: patients afflicted with Duchenne muscular dystrophy commonly exhibit NFκB-mediated inflammatory morbidity, for which they are treated with glucocorticoids; and the recently developed anti-inflammatory steroid VBP15 reduces muscular dystrophy in mdx mice, and does so by inhibiting the NFκB pathway, and does not cause the deleterious side effects of glucocorticoid-based therapeutics that are related to immune function (50). The gene discussed is NFKB1; the disease is Duchenne muscular dystrophy.